ATC Group: N07XX04 Hydroxybutyric acid

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N07XX04 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N07 Other nervous system drugs
3 N07X Other nervous system drugs
4 N07XX Other nervous system drugs
5 N07XX04 Hydroxybutyric acid

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 7.5 g

Active ingredients in N07XX04

Active Ingredient Description
Sodium oxybate

Related product monographs

Title Information Source Document Type  
XYREM Solution FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.